Full Text View
Tabular View
Study Results
Related Studies
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
This study has been terminated.
( Recruitment stopped according to early stopping rule (by protocol) )
Study NCT00597116   Information provided by AstraZeneca

First Received on January 9, 2008.   Last Updated on September 14, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Mesothelioma
More general conditions related to this trial
Adenoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Mesothelial
Interventions listed in this trial
Vinorelbine
Vandetanib
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services